Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tricarbonyldichlororuthenium(II) dimer
- Development stage
- Preclinical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intraperitoneal (in Animal Studies), Topical (in Animal Studies Via Liposomal Formulation)
01
Overview
CORM-2 (tricarbonyldichlororuthenium(II) dimer) is a small molecule pro-drug that acts as a carbon monoxide (CO)-releasing molecule. It is used in research to deliver controlled amounts of CO to biological systems. CORM-2 exhibits anti-inflammatory, antioxidant, and cytoprotective effects in various experimental models. Its mechanism of action involves the release of CO, which modulates inflammation by inhibiting cytokine production and oxidative stress responses. CORM-2 has demonstrated protective effects against acute pancreatitis, cisplatin-induced ototoxicity, skin inflammation, and bacterial biofilm formation by Pseudomonas aeruginosa[1][3][4][5][6]. It is not approved for clinical use but is widely used as a tool compound in preclinical studies.
- Other names
- CO-releasing molecule-2carbon monoxide releasing molecule-2
02
Targets
Heme iron in cytochromes and other heme-containing proteinssGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on tricarbonyldichlororuthenium(II) dimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tricarbonyldichlororuthenium(II) dimer.